Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
about
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanomaAnalysis of the genome to personalize therapy for melanomaMelanoma-restricted genesForecasting the cytokine storm following systemic interleukin (IL)-2 administrationPolymorphism in clinical immunology - From HLA typing to immunogenetic profilingGene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administrationFibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialAnticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12The past, present and future of immunotherapy against tumorNew perspectives on the role of vitiligo in immune responses to melanomaAdoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlookReflections upon human cancer immune responsiveness to T cell-based therapyMolecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma.Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyTemozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Immunologic functions as prognostic indicators in melanomaLocation, location, location: The relationship of anatomic site, antigen expression, and T-cell infiltration in human melanoma metastasesAssociation of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survivalT cell avidity and tumor immunity: problems and solutionsLigand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunityTherapy for metastatic melanoma: the past, present, and future.Immunotherapy for metastatic solid cancersEfficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma.Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trialRandomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancerTargeted therapy for melanoma: a primer.The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsetsSerologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfaImmunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigensClinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience.Novel therapeutic agents under investigation for malignant melanoma.Adoptive-cell-transfer therapy for the treatment of patients with cancerDeterminants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Thyroid dysfunction from antineoplastic agents.Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma
P2860
Q24548019-362C176E-A36D-4AA5-9EDB-1B1D6BC5A50CQ24601008-31B9F8B4-658D-4D1B-A2CC-75DD86132D7CQ24793788-30483059-0818-4B60-AE8F-F2A1B26407D2Q24796741-1616162E-7626-41E6-B2F3-7FD5E373448BQ24798836-9A927BF4-DEBF-44C0-97BF-E188D965B0D0Q24802736-DFC58DF5-DE1D-494E-9A2A-927C4C286788Q24807379-6F293A61-702A-4B14-92CE-C9F97A3C5F5EQ26796316-B55A5448-B73E-487F-9330-7D31CA1D89EAQ26799896-771DFF17-F820-4FD6-BA73-5CB8FD9D343BQ26996799-59182A53-E7BF-4D66-A544-FEE056F89ABCQ27004178-284509C4-0122-49D9-9013-1F96BF9C6AAAQ27004674-5268D803-DAE0-4362-B2F0-038860C319E2Q30423599-7708D6BD-8B12-4652-8560-6E0741715369Q30438965-D9669E42-7982-4372-8F52-8AD49D1D8382Q33346715-04639F66-74B3-4329-B5CD-5D82D2C20803Q33464837-064A4C48-0063-4D2C-8318-68ABFEEF930DQ33492805-5FCF4BAB-C7A7-4BD1-8EEE-89FD806F2E8FQ33835011-68BF0C92-E17B-4753-B9F2-279E31AFFD0EQ33880126-4A6FF204-C6CD-4E23-AC74-0B180566C60AQ34023444-53479EF8-C991-4669-B52C-7AA704EC206CQ34115960-C84C0C00-B508-4327-87A6-ABAC4AF77053Q34153811-862889D9-AE13-4974-81A1-0E4F82215E0DQ34183225-1A94092C-BDD9-449F-A2F0-B44297E50A71Q34219970-35212064-0CEF-41B5-84EC-3B09F1C09F8DQ34300883-E79BF74F-EE40-42C6-B113-600883E0A7F5Q34335379-8BFBF627-6D86-4DE3-A764-720846FC6BDBQ34536176-DCDAB515-19AE-4CEF-9195-426149DF3B18Q34540273-88B7BFD6-0FEF-46C0-82F9-48474CB3CDDEQ34608796-AE4E4EA7-A375-4E30-A4AA-2F407C89152EQ34720087-95DDF7E6-3770-44B8-82A8-DF2BF2EE802AQ34943798-A0F8C216-4FE8-46B5-BAC1-3664C01FF2EFQ35012607-9E939B9C-1C26-4B89-93DC-B6459AA5169CQ35020518-F09E2918-29C2-4413-9C1C-2FD222C2E037Q35190921-62740774-8AEF-4F6F-AC9F-DB9844095AB9Q35196765-84F1BE2B-37DD-4F9D-B738-897DAB90D80BQ35207632-39505D8E-AD7D-4758-B5A4-1D4EAA9DA739Q35210008-08F75CFC-0B3F-4972-8E5F-80405BD39AEBQ35223241-E3EF7E98-BDB1-4832-BDEC-668EA8143170Q35500038-459C3DEA-52A1-4BB1-BA8D-170A482D0B1EQ35621653-CB03BC8E-EC48-496E-B9BC-EAA9920D02AA
P2860
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Factors associated with respon ...... ents with metastatic melanoma.
@en
Factors associated with respon ...... ents with metastatic melanoma.
@nl
type
label
Factors associated with respon ...... ents with metastatic melanoma.
@en
Factors associated with respon ...... ents with metastatic melanoma.
@nl
prefLabel
Factors associated with respon ...... ents with metastatic melanoma.
@en
Factors associated with respon ...... ents with metastatic melanoma.
@nl
P2093
P1476
Factors associated with respon ...... ents with metastatic melanoma.
@en
P2093
S A Rosenberg
S M Steinberg
P304
P356
10.1200/JCO.2001.19.15.3477
P407
P577
2001-08-01T00:00:00Z